StreetAlpha.app
Home › Stocks › KRRO

Korro Bio, Inc. (KRRO)

$12.32
▼ −3.07%
LAST CLOSE · NOV 17

Korro Bio develops RNA editing medicines for rare and common diseases, with its programs still in research or preclinical stages. It last closed at $12.32 on Nov 17, down 3.07% on the day.

AI Auto Pilots
Is KRRO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.3M
−82.5% vs a year ago
Net income
−$106.1M
−8214.5% margin
EPS (diluted)
−$8.89
Free cash flow
−$63.9M
−4943.8% margin
Valuation
Market cap
$169.1M
13.7M shares
P/E
–
No P/E while losing money
Price to sales
130.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$40.2M
At Sep 30
Shares outstanding
13.7M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $14.1M$14.1MFY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $2.3M$2.3MFY2024FY2025: $6.4M$6.4MFY2025

From KRRO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated KRRO in the past 90 days, not enough for a consensus
Average 12-month target
$15.00
▲ 21.8% upside

Based on 1 analyst who set a price target on KRRO in the past 90 days. The average target is $15.00, with a high of $15.00 and a low of $15.00, compared with the last close of $12.32.

Low $15.00Avg $15.00High $15.00
Blue marker: last close $12.32
Highest target$15.00
Average target$15.00
Lowest target$15.00
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 20Buy$15
HC Wainwright & Co.Maintained
May 19Buy$15
CitigroupInitiated
May 18Buy$21
Raymond JamesUpgrade
Mar 13Buy$23
DateFirmActionRatingPrice target
Aug 20HC Wainwright & Co.ReiteratedBuy$15
May 19HC Wainwright & Co.MaintainedBuy$15
May 18CitigroupInitiatedBuy$21
Mar 13Raymond JamesUpgradeBuy$23
Loading…

Technical Analysis

KRRO · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 1% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 45). The nearest support is the 100 day average at $12.25, and the nearest resistance the Pivot at $12.54.

Short trendBullish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 10.4%/day
Key levels
$17.3552 week high+40.8%
$13.8420 day average+12.3%
$13.07Swing high (Jun 12)+6.1%
$12.92Pivot R1+4.9%
$12.54Pivot+1.8%
$12.32Last close
$12.25100 day average−0.6%
$12.16200 day average−1.3%
$11.97Swing low (Jun 25)−2.8%
$11.93Pivot S1−3.2%
$11.8450 day average−3.9%
$5.2052 week low−57.8%
Indicators
RSI (14)44.96Middle of its rangeNeutral
MACD0.60Below its signal lineBearish
Stochastic23.6Middle of its rangeNeutral
ADX (14)22.7Weak trend
Williams %R-86.0Oversold below −80, overbought above −20Oversold
CCI (20)-61.3Oversold below −100, overbought above 100Neutral
Rate of change−22.3%Change over 10 sessionsBearish
ATR (14)$1.28Typical daily range, 10.4% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for KRRO

What happened before

See how KRRO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow KRRO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How KRRO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in KRRO in the last 90 days.

Loading…

See today’s whale options flow across the market →

KRRO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●53 buying vs 48 selling
  • ▼Held by funds -7.8 pts
  • ▼Funds holding -3
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding105108−2.8%
In funds' top 10440.0%
Held by funds102.1%109.9%−7.8 pts
New / increased14 / 3919 / 48−20.9%
Reduced / sold out31 / 1719 / 11+60.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KRRO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRRO is in one of them and how their past KRRO trades turned out.

KRRO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KRRO in an article yet. Here's the latest on the wider market.

About Korro Bio

Korro Bio is a biopharmaceutical company based in Cambridge, Massachusetts, that is developing a new class of genetic medicines that edit RNA rather than DNA. Its approach uses engineered oligonucleotides that work with a natural cell process to make precise, temporary changes to proteins. The company aims to treat both rare and widely prevalent diseases, including urea cycle disorders, liver conditions and ALS, but its programs are still in research or preclinical development.

Headquarters
Cambridge, MA